Page last updated: 2024-11-05
triamterene and Disease Exacerbation
triamterene has been researched along with Disease Exacerbation in 1 studies
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.
triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Both amiloride and triamterene significantly reduced proteinuria in patients with proteinuric kidney disease." | 9.41 | The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease. ( Alshehri, M; Desale, S; Shen, W; Wilcox, C, 2021) |
| "Both amiloride and triamterene significantly reduced proteinuria in patients with proteinuric kidney disease." | 5.41 | The Effect of Amiloride on Proteinuria in Patients with Proteinuric Kidney Disease. ( Alshehri, M; Desale, S; Shen, W; Wilcox, C, 2021) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Shen, W | 1 |
| Alshehri, M | 1 |
| Desale, S | 1 |
| Wilcox, C | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease[NCT02522650] | Phase 4 | 30 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for triamterene and Disease Exacerbation